A stuntman knew his body was changing. It took doctors nearly a decade to figure out why.
When Ray Kohn started feeling pain in his knees and elbows in 2015, he attributed it to his work as a stunt driver and ...
Too Old to Operate4d
Pasireotide Response and Metabolic Effects in Acromegaly Management
The following is a summary of “Paradoxical GH response at OGTT does not predict Pasireotide efficacy but matters for glucose metabolism,” published in the January 2025 issue of Endocrinology by Occhi ...
Nature9d
Acromegaly And Pregnancy Management
Acromegaly is a rare hormonal disorder that results from excess growth hormone, often due to a pituitary adenoma. Managing pregnancy in women with acromegaly poses unique challenges and concerns ...
Billionaire Joseph Edelman’s Top 10 Long-Term Stock Picks
Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare ...
Team PGI achieves 3 milestones, world’s first tech report of endoscopic skull published
Chandigarh: Team PGIMER, led by Prof Dhandapani SS, has made groundbreaking advancements in neurosurgery by publishing three ...
Hosted on MSN10d
Jefferies Upgrades Crinetics Pharmaceuticals (CRNX)
Fintel reports that on January 22, 2025, Jefferies upgraded their outlook for Crinetics Pharmaceuticals (NasdaqGS:CRNX) from ...
Mena FN22d
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Crinetics' lead development candidate, paltusotine , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for ...
Cantor Fitzgerald Weighs in on CRNX FY2025 Earnings
Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Crinetics Pharmaceuticals in a research note issued on Tuesday, January 21st. Cantor Fitzgerald ...